SEATTLE, WA, KayoThera, a therapeutics company developing oral, small molecule inhibitors of the retinoid pathway, announced a $5.2 million Series A Extension funding round.
KayoThera, a therapeutics company developing oral, small molecule inhibitors of the retinoid pathway, announced a $5.2 million Series A Extension funding round.
KayoThera secured the additional Series A financing in an expansion round led by ALSP that also included participation from BioAdvance, Pier 70 Ventures, and WRF Capital.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
